149 related articles for article (PubMed ID: 25678804)
1. Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.
Parker AR; Petluru PN; Nienaber VL; Zhao M; Ayala PY; Badger J; Chie-Leon B; Sridhar V; Logan C; Kochat H; Hausheer FH
Onco Targets Ther; 2015; 8():375-83. PubMed ID: 25678804
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
Hausheer FH; Shanmugarajah D; Leverett BD; Chen X; Huang Q; Kochat H; Petluru PN; Parker AR
Cancer Chemother Pharmacol; 2010 Apr; 65(5):941-51. PubMed ID: 19714332
[TBL] [Abstract][Full Text] [Related]
3. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
Parker AR; Petluru PN; Wu M; Zhao M; Kochat H; Hausheer FH
Mol Cancer Ther; 2010 Sep; 9(9):2558-67. PubMed ID: 20807779
[TBL] [Abstract][Full Text] [Related]
4. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
5. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
Shanmugarajah D; Ding D; Huang Q; Chen X; Kochat H; Petluru PN; Ayala PY; Parker AR; Hausheer FH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):857-66. PubMed ID: 19278906
[TBL] [Abstract][Full Text] [Related]
6. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
8. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
9. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
Lei YY; Yang JJ; Zhang XC; Zhong WZ; Zhou Q; Tu HY; Tian HX; Guo WB; Yang LL; Yan HH; Chen HJ; Xie Z; Su J; Han JF; Wu YL
Clin Lung Cancer; 2016 May; 17(3):223-31. PubMed ID: 26454342
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
12. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
13. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of BNP7787 in human renal proximal tubule cells.
Hausheer FH; Ding D; Shanmugarajah D; Leverett BD; Huang Q; Chen X; Kochat H; Ayala PY; Petluru PN; Parker AR
J Pharm Sci; 2011 Sep; 100(9):3977-84. PubMed ID: 21344411
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
[TBL] [Abstract][Full Text] [Related]
17. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
[TBL] [Abstract][Full Text] [Related]
18. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
Boven E; Westerman M; van Groeningen CJ; Verschraagen M; Ruijter R; Zegers I; van der Vijgh WJ; Giaccone G
Br J Cancer; 2005 May; 92(9):1636-43. PubMed ID: 15841080
[TBL] [Abstract][Full Text] [Related]
20. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
